NEW YORK – Transgene and NEC Corporation announced Monday that they have advanced Transgene's immunotherapy vaccine TG4050 into two Phase I trials for patients with human papillomavirus-negative, squamous cell head and neck cancer who are at high risk of relapse after surgery, and ovarian cancer patients who have received first-line therapy after surgery.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.